Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Vir Biotechnology Inc’s stock clocked out at $5.6, down -6.04% from its previous closing price of $5.96. In other words, the price has decreased by -$6.04 from its previous closing price. On the day, 1.43 million shares were traded. VIR stock price reached its highest trading level at $5.97 during the session, while it also had its lowest trading level at $5.5.
Ratios:
To gain a deeper understanding of VIR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 7.01. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Evercore ISI on September 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $12.
On August 27, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $14.
JP Morgan Downgraded its Overweight to Neutral on January 29, 2024, whereas the target price for the stock was revised from $23 to $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when de Verneuil Vanina bought 1,365 shares for $5.86 per share.
SVF Endurance (Cayman) Ltd sold 24,453 shares of VIR for $159,006 on Oct 28 ’25. The 10% Owner now owns 14,574,083 shares after completing the transaction at $6.50 per share. On Oct 29 ’25, another insider, SVF Endurance (Cayman) Ltd, who serves as the 10% Owner of the company, sold 100 shares for $6.49 each. As a result, the insider received 649 and left with 14,573,983 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 777932032 and an Enterprise Value of 274142976. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.94 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at 14.429 whereas that against EBITDA is -0.494.
Stock Price History:
The Beta on a monthly basis for VIR is 1.27, which has changed by -0.38174272 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is 1.76%, while the 200-Day Moving Average is calculated to be -9.57%.
Shares Statistics:
It appears that VIR traded 1.41M shares on average per day over the past three months and 1655650 shares per day over the past ten days. A total of 138.89M shares are outstanding, with a floating share count of 92.60M. Insiders hold about 33.36% of the company’s shares, while institutions hold 56.97% stake in the company. Shares short for VIR as of 1760486400 were 10940671 with a Short Ratio of 7.76, compared to 1757894400 on 11852892. Therefore, it implies a Short% of Shares Outstanding of 10940671 and a Short% of Float of 12.690000000000001.
Earnings Estimates
The stock of Vir Biotechnology Inc (VIR) is currently in the spotlight, with 7.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.59 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$2.87 and -$3.84 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$2.88, with 8.0 analysts recommending between -$2.4 and -$3.54.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $2.05M. There is a high estimate of $3.9M for the next quarter, whereas the lowest estimate is $500k.
A total of 9 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $37M, while the lowest revenue estimate was $4.7M, resulting in an average revenue estimate of $11.47M. In the same quarter a year ago, actual revenue was $74.2MBased on 9 analysts’ estimates, the company’s revenue will be $13.22M in the next fiscal year. The high estimate is $29.65M and the low estimate is $3M.
